My paper on statistical disease progression modeling in Alzheimer's disease has just been published in Frontiers in AI & Big Data. You can find it here doi.org/10.3389/fdata.… Want to try it out on your own data? Code can be found here github.com/larslau/progmod

Looking forward to the Harvard Medical School #dementia research update conference in September 2022. #geriatrics American Geriatrics Society cmecatalog.hms.harvard.edu/dementia-compr…

Are you interested in how one can estimate more interpretable treatment effects of disease modifying therapies in #Alzheimers #clinicaltrials? Then join my #AAIC22 talk in the session 'Novel Clinical Trial Designs and Outcome Measures' on Aug 2, 10am #DaDaPIA Alzheimer's Association

How can one jointly estimate a time-consistent trajectory of multiple biomarkers' evolution over the #Alzheimers continuum? And how do results compare across cohorts? Find out in my #AAIC22 talk in the 'Modelling AD trajectories using biomarkers' session on Aug 4, 8am #DaDaPIA

Important take away messages for amyloid lowering therapies in AD by Alireza Atri #AAIC22

WHO launches today an important initiative to sensitise governments to #brainhealth. #dementia and #alzheimers are part of this. It’s amazing that we still know so little about the brain and how it works, but I think this is why many governments have ignored this area for so long

For fluid BM aficionados: DADM recently published an editorial and two papers discussing fluid BM variability by race and in those with liver/kidney failure. There is so much we need to learn still! Please share widely. Links to the papers are in the chat below. #ENDALZ

BEST NEWS EVER! I am so happy for our patients. At long last we have a positive trial. eisai.com/news/2022/news…

Persons with #Parkinson disease were found to be at four times the risk of #dementia compared to sex and age matched persons w/o #Parkinsons using Swedish Registry data. PD is not just disease that impacts motor functions.

About 1 in 5 of us have an APOE4 gene variant, the #1 genetic risk factor for Alzheimer's disease. But the mechanism for brain injury was a mystery, now getting unraveled (cholesterol processing by oligodendrocytes) nature.com/articles/s4158… @nature nature.com/articles/d4158…

Caution needed as usual, but the results just published on Lecanemab, a possible breaktrough therapy for the early stages of #alzheimers do look promising. For a full analysis look at our alzint.org later on. Alireza Atri ADI nejm.org/doi/full/10.10…

This is something I have wanted to do from the first month I started at ADI. It is so important as so many countries refuse to reimburse the few meds we have available. Those meds are now out of patent and affordable. Thanks to Professor Louise Robinson Martin Knapp and Alireza Atri

If you are prescribed hearing aids please wear them! Further evidence this month points to a correlation between correcting hearing problems and reduction in cognitive decline and eventually #dementia #hearingloss

Lecanemab - to be called Leqembi has received approval from the US Food and Drug Administrattin for those living with #dementia with mild cognitive impairment or mild dementia. Good news for our community, still a lot of work to do on equity of access…

Please help Alzheimer's Jamaica and many other organisations get proper #dementia and #alzheimers plans and strategies for their countries join ADI #WhatsYourPlan campaign at alzint.org/news-events/ne… repost our posts, make more people aware, put pressure on governments

¡Únase a Alireza Atri- uno de los científicos más ocupados del mundo en la búsqueda de un tratamiento para el Alzheimer y la demencia- y yo en una conversación hoy a las 13, hora de Londres!